Healthcare | Fri Mar 13, 2015 | 2:42am EDT
BRIEF-Weifa to spin-off B2B business
March 13 Weifa ASA :
* Proposes separation of Consumer Health and Business-to-Business (B2B)
* Intends to separate company's Consumer Health and B2B operations through a sale of its B2B business and tablet production to Vistin Pharma
* Vistin Pharma is a newly established subsidiary of Weifa, which will seek listing on Oslo Axess
* Says Vistin Pharma will conduct an equity issue of about 170 million Norwegian crowns ($20.86 million) to finance B2B acquisition
* About 120 million crowns of proceeds from equity issue will be paid to Weifa as consideration for B2B business
* Current CEO of Weifa, Kjell-Erik Nordby, will be appointed CEO of Vistin Pharma  Source text for Eikon:  Further company coverage:   ($1 = 8.1499 Norwegian crowns)   (Gdynia Newsroom)
Next In Healthcare
